• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    From Nokia to NeOnc: The Stocks Dominating Screens as Volume Spikes

    6/12/26 11:40:15 AM ET
    $AKAN
    $DSY
    $NOK
    $NTHI
    Medicinal Chemicals and Botanical Products
    Health Care
    Containers/Packaging
    Consumer Discretionary
    Get the next $AKAN alert in real time by email

    DENVER, June 12, 2026 (GLOBE NEWSWIRE) -- 247marketnews.com- Volume often tells investors where attention is flowing before the broader market fully recognizes a developing story. While each story is very different, all share one common trait: investors are watching closely for what comes next.

    Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store.

    Nokia Corporation

    Few companies have undergone a more dramatic transformation than Nokia (NYSE:NOK). Once viewed primarily as a telecom equipment provider, Nokia has increasingly positioned itself as a critical supplier of optical networking, AI infrastructure, cloud connectivity, and data-center networking solutions. The company's acquisition of Infinera significantly expanded its optical networking capabilities and strengthened its position within the rapidly growing AI infrastructure buildout.

    The strategy appears to be gaining traction. Nokia recently reported strong demand from AI and cloud customers, including approximately €1 billion in new orders. Management raised its Network Infrastructure growth outlook to 12%-14% from a previous forecast of 6%-8%, citing strength in optical and IP networking businesses. The company has also benefited from a strategic investment by NVIDIA and growing demand from hyperscalers building AI data centers that require high-performance optical connectivity. Shares recently reached their highest levels in approximately 16 years following earnings results that exceeded expectations.

    NeOnc Technologies Holdings

    NeOnc (NASDAQ:NTHI) continues to attract attention among speculative biotech investors focused on central nervous system oncology. The company is developing therapies designed to address glioblastoma and other aggressive brain cancers, areas where treatment options remain limited and unmet medical need remains substantial. Its pipeline includes NEO100 and NEO212, programs aimed at improving treatment approaches for difficult-to-treat brain tumors.

    Recent investor interest has centered on both financing activity and corporate developments. The company disclosed a new private placement allowing for up to $5 million of Series A Convertible Preferred Stock. While the financing includes a discounted conversion feature if not redeemed, it also contains several provisions some investors may view as shareholder-friendly, including a company redemption option, ownership limitations, and a conversion floor price. Investors continue monitoring future clinical, regulatory, and financing developments that could serve as catalysts.

    Akanda Corp.

    Akanda (NASDAQ:AKAN) recently drew attention following developments surrounding its Nasdaq compliance status. The company had previously received a notice regarding delayed filing of its annual Form 20-F. After filing the required report, the company announced that Nasdaq determined the matter had been resolved and compliance was restored, removing a significant overhang that many investors closely monitor when evaluating smaller-cap companies.

    Beyond cannabis operations, Akanda's evolving corporate structure has generated additional investor interest. The company has highlighted telecommunications infrastructure opportunities through First Towers & Fiber Corp., which operates a substantial fiber optic network in Mexico and has expressed intentions to expand throughout Latin America. While the company remains a speculative investment, traders often react strongly when compliance concerns are removed and new infrastructure-related growth narratives emerge.

    Big Tree Cloud Holdings

    Big Tree Cloud (NASDAQ:DSY) is the latest Chinese madness listing without news. This has been a common theme this week, following the PDT rule changes. 

    Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store.

    About 24/7 Market News

    In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company's profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company's visibility and valuation trajectory.

    This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor. For the full disclosure, please visit: https://go.247marketnews.com/nthi-disclosure/

    For further information, please visit 247marketnews.com.

    CONTACT:

    24/7 Market News

    Editor@247marketnews.com

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.



    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $DSY
    $NOK
    $NTHI

    CompanyDatePrice TargetRatingAnalyst
    NeOnc Technologies Holdings Inc.
    $NTHI
    5/19/2026$13.00Buy
    Alliance Global Partners
    NeOnc Technologies Holdings Inc.
    $NTHI
    5/18/2026$20.00Buy
    Maxim Group
    Nokia Corporation Sponsored
    $NOK
    4/29/2026Neutral → Buy
    Arete
    Nokia Corporation Sponsored
    $NOK
    4/27/2026$15.00Hold → Buy
    Argus
    NeOnc Technologies Holdings Inc.
    $NTHI
    4/24/2026$15.00Buy
    BTIG Research
    Nokia Corporation Sponsored
    $NOK
    4/24/2026Hold → Buy
    Nordea
    Nokia Corporation Sponsored
    $NOK
    4/24/2026Sell → Hold
    Danske Bank
    Nokia Corporation Sponsored
    $NOK
    4/13/2026$12.40Neutral → Buy
    BofA Securities
    More analyst ratings

    $AKAN
    $DSY
    $NOK
    $NTHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on NeOnc Technologies Holdings with a new price target

    Alliance Global Partners initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $13.00

    5/19/26 8:31:51 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on NeOnc Technologies Holdings with a new price target

    Maxim Group initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $20.00

    5/18/26 8:44:12 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nokia upgraded by Arete

    Arete upgraded Nokia from Neutral to Buy

    4/29/26 8:00:57 AM ET
    $NOK
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $AKAN
    $DSY
    $NOK
    $NTHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Heshmatpour Amir F bought $41,592 worth of shares (10,000 units at $4.16), increasing direct ownership by 0.33% to 3,072,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    5/4/26 2:08:58 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Heshmatpour Amir F bought $45,180 worth of shares (10,000 units at $4.52), increasing direct ownership by 0.33% to 3,062,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    4/28/26 6:00:05 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Clinical Officer Neman-Ebrahim Yousha bought $2,440 worth of shares (500 units at $4.88), increasing direct ownership by 0.37% to 134,760 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    4/24/26 6:10:07 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $DSY
    $NOK
    $NTHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum

    DENVER, June 24, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is entering one of the most significant periods in its corporate history after securing its second Investigational New Drug (IND) authorization from the United Arab Emirates this month, further expanding international development opportunities for its central nervous system cancer pipeline. The latest authorization from the Department of Health – Abu Dhabi grants IND status to NEO100, NeOnc's lead intranasal therapy candidate for recurrent high-grade gliomas. Importantly, the authorization spans three separate clinical protocols, adult studies ranging from Phase 1 through Phase 2, an

    6/24/26 8:45:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    These Emerging Companies Are Racing Toward Major Catalysts

    DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points. NeOnc Technologies Approaches Major Clinical Catalyst NeOnc Technologies (NASDAQ:NTHI) has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Pha

    6/23/26 11:11:05 AM ET
    $NTHI
    $BOLD
    $BLZE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

    Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc’s UAE footprint beyond NEO212 and complements ongoing U.S. development, where NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations CALABASAS, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO100, the Company’s lead candidate, an intranasally a

    6/23/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $DSY
    $NOK
    $NTHI
    SEC Filings

    View All

    SEC Form EFFECT filed by NeOnc Technologies Holdings Inc.

    EFFECT - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    6/24/26 12:15:13 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by NeOnc Technologies Holdings Inc.

    DEFA14A - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    6/23/26 5:09:40 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by NeOnc Technologies Holdings Inc.

    DEF 14A - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    6/23/26 5:08:57 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $DSY
    $NOK
    $NTHI
    Leadership Updates

    Live Leadership Updates

    View All

    Penguin Solutions Strengthens AI Factory Platform Strategy with Appointment of David Heard to Board of Directors

    Penguin Solutions, Inc. ("Penguin Solutions" or the "Company") (Nasdaq: PENG), the AI Factory Platform company, today announced that David Heard, President of Network Infrastructure at Nokia, has been appointed to Penguin Solutions' board of directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518589175/en/David Heard, President of Network Infrastructure at Nokia, has been appointed to Penguin Solutions' board of directors. His track record of operational execution and scaling global businesses is expected to complement the board's expertise as Penguin Solutions continues to converge its capabiliti

    5/18/26 4:15:00 PM ET
    $INFN
    $NOK
    $PENG
    Telecommunications Equipment
    Utilities
    Radio And Television Broadcasting And Communications Equipment
    Technology

    NeOnc Technologies Appoints David Choi as Chief Accounting Officer

    CALABASAS, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, has appointed David Choi as Chief Accounting Officer. In this role, Mr. Choi is responsible for overseeing the Company's accounting, financial reporting, internal controls, and corporate governance functions as NeOnc advances its clinical-stage biotechnology platform and expands its global operations. "David's extensive expertise in technical accounting and financial reporting for public companies comes at a pivotal time for NeOnc," said

    3/13/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sharon AI Appoints Mr. Benjamin Adams to Board of Directors

    SharonAI Holdings Inc. ("Sharon AI"), a leading Australian neocloud (NASDAQ:SHAZ), announced on February 24, 2026, that highly experienced global technology executive, Mr. Benjamin Adams, joined the Sharon AI Holdings Inc. board of directors on February 22, 2026. Mr. Adams is a global business and technology leader with deep and broad expertise across financial, technology and regulatory law, mergers & acquisitions, corporate securities reporting, intellectual property and real estate. "I am honoured to join the board at such a pivotal and exciting time. I look forward to leveraging my experience to help Sharon AI shape its strategic goals and expand its impact in the coming years," sai

    3/3/26 7:30:00 AM ET
    $MSFT
    $NOK
    $PYPL
    Computer Software: Prepackaged Software
    Technology
    Radio And Television Broadcasting And Communications Equipment
    Diversified Commercial Services

    $AKAN
    $DSY
    $NOK
    $NTHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Akanda Corp. (Amendment)

    SC 13D/A - AKANDA CORP. (0001888014) (Subject)

    2/20/24 6:01:03 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Akanda Corp.

    SC 13D - AKANDA CORP. (0001888014) (Subject)

    2/20/24 5:17:13 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Akanda Corp. (Amendment)

    SC 13G/A - AKANDA CORP. (0001888014) (Subject)

    2/20/24 12:55:32 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    $DSY
    $NOK
    $NTHI
    Financials

    Live finance-specific insights

    View All

    NeOnc Provides Business Update and Reports Q1 2026 Financial Results

    CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company advancing two Phase 2 programs in central nervous system (CNS) cancers, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent operational achievements and upcoming milestones. Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President, commented: "The first quarter of 2026 marked a transformational period for NeOnc as we advanced both of our lead clinical programs toward important regulatory and value-creation milestones. We successfully comp

    5/18/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

    CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET. NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day cycle) following a second

    3/4/26 8:00:00 AM ET
    $MRK
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

    CALABASAS, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced today announced that it will host an investor conference call and webcast on March 4, 2026, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time. During the call, members of the NeOnc management team and independent members of the Company's Scientific Advisory Board (SAB) will present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial, evaluating NeOnc's proprietary bioconjugated

    2/27/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $DSY
    $NOK
    $NTHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Heshmatpour Amir F bought $41,592 worth of shares (10,000 units at $4.16), increasing direct ownership by 0.33% to 3,072,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    5/4/26 2:08:58 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Heshmatpour Amir F bought $45,180 worth of shares (10,000 units at $4.52), increasing direct ownership by 0.33% to 3,062,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    4/28/26 6:00:05 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Clinical Officer Neman-Ebrahim Yousha bought $2,440 worth of shares (500 units at $4.88), increasing direct ownership by 0.37% to 134,760 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    4/24/26 6:10:07 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care